Literature DB >> 2753902

Ca2+-dependent binding of a synthetic Arg-Gly-Asp (RGD) peptide to a single site on the purified platelet glycoprotein IIb-IIIa complex.

B Steiner1, D Cousot, A Trzeciak, D Gillessen, P Hadváry.   

Abstract

The platelet glycoprotein IIb-IIIa complex (GP IIb-IIIa) is a member of the integrin receptor family that recognizes adhesive proteins containing the Arg-Gly-Asp (RGD) sequence. In the present study the binding characteristics of the synthetic hexapeptide Tyr-Asn-Arg-Gly-Asp-Ser (YNRGDS, a sequence present in the fibrinogen alpha-chain at position 570-575) to purified GP IIb-IIIa were determined by equilibrium dialysis. The binding of 125I-YNRGDS to GP IIb-IIIa was specific, saturable, and reversible. The apparent dissociation constant was 1.0 +/- 0.2 microM, and the maximal binding capacity was 0.92 +/- 0.02 mol of 125I-YNRGDS/mol of GP IIb-IIIa, indicating that GP IIb-IIIa contains a single binding site for RGD peptides. The binding of 125I-YNRGDS to purified GP IIb-IIIa showed many of the characteristics of fibrinogen binding to activated platelets: the binding was inhibited by fibrinogen, by the monoclonal antibody A2A9, and by the dodecapeptide from the C terminus of the fibrinogen gamma-chain. In addition, the binding of 125I-YNRGDS to GP IIb-IIIa was divalent cation-dependent. Our data suggest that two divalent cation binding sites must be occupied for YNRGDS to bind: one site is specific for calcium and is saturated at 1 microM free Ca2+, whereas the other site is less specific and reaches saturation at millimolar concentrations of either Ca2+ or Mg2+. The results of the present study support the hypothesis that the RGD domains within the adhesive proteins are responsible for their binding to GP IIb-IIIa.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2753902

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Role of extracellular ionized calcium in the in vitro assessment of GPIIb/IIIa receptor antagonists.

Authors:  S S Rebello; J Huang; J D Faul; B R Lucchesi
Journal:  J Thromb Thrombolysis       Date:  2000-01       Impact factor: 2.300

2.  Calcium binding to human platelet integrin GPIIb/IIIa and to its constituent glycoproteins. Effects of lipids and temperature.

Authors:  G A Rivas; J González-Rodríguez
Journal:  Biochem J       Date:  1991-05-15       Impact factor: 3.857

3.  The effect of glycoprotein IIIa PIA 1/A2 polymorphism on the PFA-100 response to GP IIb IIa receptor inhibitors-the importance of anticoagulants used.

Authors:  Katriina Aalto-Setälä; Pekka J Karhunen; Jussi Mikkelsson; Kari Niemelä
Journal:  J Thromb Thrombolysis       Date:  2005-08       Impact factor: 2.300

4.  Regulation of ligand binding to glycoprotein IIb-IIIa (integrin alpha IIb beta 3) in isolated platelet membranes.

Authors:  S S Smyth; L V Parise
Journal:  Biochem J       Date:  1993-06-15       Impact factor: 3.857

5.  Experimental support for a beta-propeller domain in integrin alpha-subunits and a calcium binding site on its lower surface.

Authors:  C Oxvig; T A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

6.  Proteolytic degradation of the RGD-binding and non-RGD-binding conformers of human platelet integrin glycoprotein IIb/IIIa: clues for identification of regions involved in the receptor's activation.

Authors:  J J Calvete; K Mann; W Schäfer; R Fernandez-Lafuente; J M Guisán
Journal:  Biochem J       Date:  1994-02-15       Impact factor: 3.857

7.  Calcium and temperature regulation of the stability of the human platelet integrin GPIIb/IIIa in solution: an analytical ultracentrifugation study.

Authors:  G A Rivas; P Usobiaga; J González-Rodriguez
Journal:  Eur Biophys J       Date:  1991       Impact factor: 1.733

8.  Ser-752-->Pro mutation in the cytoplasmic domain of integrin beta 3 subunit and defective activation of platelet integrin alpha IIb beta 3 (glycoprotein IIb-IIIa) in a variant of Glanzmann thrombasthenia.

Authors:  Y P Chen; I Djaffar; D Pidard; B Steiner; A M Cieutat; J P Caen; J P Rosa
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

9.  Prevention of experimental carotid and coronary artery thrombosis by the glycoprotein IIb/IIIa receptor antagonist CRL42796.

Authors:  James K Hennan; Ting-Ting Hong; David E Willens; Edward M Driscoll; Thierry A Giboulot; Benedict R Lucchesi
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

10.  Tetrafibricin, a novel non-peptide fibrinogen receptor antagonist, induces conformational changes in glycoprotein IIb/IIIa.

Authors:  T Satoh; W C Kouns; Y Yamashita; T Kamiyama; B Steiner
Journal:  Biochem J       Date:  1994-08-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.